source
- Sellas cancer vaccine cuts death risk by 41% in late-stage AML trialSellas Life Sciences announced results from its Phase 3 REGAL trial evaluating an off‑the‑shelf cancer vaccine in patients with acute myeloid leukemia (AML). The study enrolled 126 individuals who…
- AriBio's AR1001 shows 31% slower cognitive decline in monotherapy Phase 3 trialAriBio presented data at the 2026 Clinical Trials on Alzheimer's Disease conference indicating its candidate AR1001 slowed cognitive decline compared with placebo in patients not taking other Alzhe…